Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis

被引：0

作者：

Steinman, Lawrence ^{[1
]}

Fox, Edward ^{[2
]}

Hartung, Hans-Peter ^{[3
]}

Cree, Bruce ^{[4
]}

Alvarez, Enrique ^{[5
]}

Qian, Peiqing ^{[6
]}

Wray, Sibyl ^{[7
]}

Robertson, Derrick ^{[8
]}

Huang, Deren ^{[9
]}

Selmaj, Krzystof ^{[10
]}

Wynn, Daniel ^{[11
]}

Weiss, Michael ^{[12
]}

Bosco, Jenna ^{[12
]}

Power, Sean ^{[12
]}

Mok, Koby ^{[12
]}

机构：

[1] Stanford Univ, Stanford, CA 94305 USA

[2] Cent Texas Neurol Consultants, Round Rock, TX USA

[3] Heinrich Heine Univ, Dusseldorf, Germany

[4] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA

[5] Univ Colorado, Boulder, CO 80309 USA

[6] Swedish Med Ctr, Englewood, CO 80110 USA

[7] Hope Neurol, Knoxville, TN USA

[8] Univ S Florida, Morsani Coll Med, Tampa, FL 33620 USA

[9] Mt Carmel Neurol, Westerville, OH USA

[10] Med Acad Lodz, Lodz, Poland

[11] Consultants Neurol Ltd, Northbrook, IL USA

[12] TG Therapeut, New York, NY USA

来源：

NEUROLOGY | 2020年 / 94卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

4845

引用

页数：4

共 50 条

[31] UBLITUXIMAB (TG-1101), A NOVEL GLYCOENGINEERED ANTI-CD20 MAB, IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH CLL AND MCL; RESULTS OF AN ONGOING PHASE II TRIAL
Sharman, J. P.
Farber, C. M.
Mahadevan, D.
Schreeder, M. T.
Mackenzie, M.
Brotherton, M.
Pauli, E. K.
Cutter, K.
Sportelli, P.
Miskin, H. P.
O'Connor, O. A.
HAEMATOLOGICA, 2014, 99 : 326 - 327
[32] Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 mAb, in Patients with RMS
Fox, Edward
Wray, Sibyl
Shubin, Richard
Huang, Deren
Bass, Ann
Weiss, Michael
Power, Sean
Bosco, Jenna
Mok, Koby
NEUROLOGY, 2020, 94 (15)
[33] Characteristics of Patients Switching from Anti-CD20 Therapy to Natalizumab in the Treatment of Multiple Sclerosis
Vollmer, Brandi
Nair, Kavita
Corboy, John
Vollmer, Timothy
Alvarez, Enrique
NEUROLOGY, 2019, 92 (15)
[34] Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
Coiffier, B
Haioun, C
Ketterer, N
Engert, A
Tilly, H
Ma, D
Johnson, P
Lister, A
Feuring-Buske, M
Radford, JA
Capdeville, R
Diehl, V
Reyes, F
BLOOD, 1998, 92 (06) : 1927 - 1932
[35] Title: Long-term Follow-up Results From The Phase 2 Multicenter Study Of Ublituximab (utx), A Novel Glycoengineered Anti-cd20 Mab, In Patients With Rms
Fox, E.
Shubin, R.
Bass, A.
Huang, D.
Lovett-Racke, A.
Weiss, M. S.
Bosco, J.
Power, S.
Mok, K.
Wray, S.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 51 - 51
[36] Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
Sharman, Jeff P.
Farber, Charles M.
Mahadevan, Daruka
Schreeder, Marshall T.
Brooks, Heather D.
Kolibaba, Kathryn S.
Fanning, Suzanne
Klein, Leonard
Greenwald, Daniel R.
Sportelli, Peter
Miskin, Hari P.
Weiss, Michael S.
Burke, John M.
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (03) : 412 - 420
[37] Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma
Grunenberg, Alexander
Kaiser, Lisa M.
Woelfle, Stephanie
Schmelzle, Birgit
Viardot, Andreas
Moeller, Peter
Barth, Thomas F. E.
Muche, Rainer
Dreyhaupt, Jens
Buske, Christian
FUTURE ONCOLOGY, 2020, 16 (13) : 817 - 825
[38] Increased use of anti-CD20 monoclonal antibodies (anti-CD20s) in early line treatments for relapsing remitting multiple sclerosis (RRMS) patients in Europe and the United States
Vindici, J.
Teoh, S.
Goh, A. J.
Gill, L.
Gabriele, S.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 878 - 878
[39] FINAL RESULTS OF A MULTICENTER PHASE IB SINGLE AGENT STUDY WITH THE NOVEL ANTI-CD20 MONOCLONAL ANTIBODY UBLITUXIMAB (TG-1101) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Cazin, B.
Lepretre, S.
Coiffier, B.
Aurran, T.
Cartron, G.
Feugier, P.
Brehar, O.
Sadoun, A.
Sportelli, P.
Miskin, H.
Ribrag, V.
HAEMATOLOGICA, 2013, 98 : 47 - 47
[40] Relative frequency of CD11c+peripheral blood B cells increases after anti-CD20 monoclonal antibody therapy in relapsing-remitting multiple sclerosis
El Mahdaoui, Sahla
Hansen, Marie Mathilde
von Essen, Marina Rode
Hvalkof, Victoria
Sellebjerg, Finn
Christensen, Jeppe Romme
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 235 - 236

← 1 2 3 4 5 →